Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts Meeting Abstract
| Authors: | Moore, K. N.; Matulonis, U. A.; O'Malley, D. M.; Konner, J. A.; Martin, L. P.; Perez, R. P.; Bauer, T. M.; Gilbert, L.; Seward, S. M.; Oza, A. M.; Ruiz-Soto, R.; Birrer, M. J. |
| Abstract Title: | Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 298s |
| Language: | English |
| ACCESSION: | WOS:000411931704025 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.5547 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 5547 -- Source: Wos |
